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Chronic kidney disease (CKD) is a common condition that is
increasing in prevalence in developed nations. The economic
and psychosocial costs of CKD are considerable, and are
associated with high levels of morbidity and mortality.
Specific treatments do not exist for many causes of CKD.
Therefore, treatment is reliant on the introduction of
therapies that retard progression of structural renal damage
and renal impairment. At present, aside from judicious use of
antihypertensive agents to lower blood pressure, and
possibly low-protein diets and statin therapy, blockade of the
renin–angiotensin–aldosterone system (RAAS) with
angiotensin-converting enzyme inhibitors (ACEis) and
angiotensin II receptor blockers (ARBs) are the only widely
available treatments. Although these measures attenuate the
inexorable progression to renal failure, they do not halt it.
One limiting factor may be feedback effects of ACEis and
ARBs, such as increased plasma renin activity. Aliskiren is a
newer agent that inhibits renin, the rate-limiting step in the
RAAS. There are several theoretical reasons to suggest that
aliskiren may have renoprotective actions superior to those
of ACEis and ARBs. In this paper the available evidence
regarding renoprotective effects of aliskiren is reviewed, with
an emphasis on comparison with ACEis and ARBs.
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Chronic kidney disease (CKD) is increasingly common in
developed nations. The number of incident patients receiving
renal replacement therapy in the form of dialysis or renal
transplantation in Australia and New Zealand increased from
1892 (96 per million population) in 2002 to 2378 (115 per
million population) in 2007.1 Similar trends have been
observed in other developed nations including the United
States2 and central and eastern Europe.3 Consequences of
CKD include increased risks of progression to end-stage
renal disease (ESRD)4 and of cardiovascular and all-cause
mortality.5
The histological feature that correlates best with serum
creatinine and predicts progressive renal impairment is
tubulointerstitial fibrosis,6 characterized by increased deposi-
tion of extracellular matrix, tubular atrophy and inflamma-
tory cell infiltrates.7,8 CKD is also characterized by
glomerulosclerosis. Although not as predictive of progressive
renal impairment as tubulointerstitial fibrosis, glomerulo-
sclerosis contributes to perpetuation of tubulointerstitial
damage and may be particularly important in the pathogen-
esis of early stages of the disease.9
Many causes of CKD do not have specific treatments. In
particular, there are no disease-modifying agents currently
available for diabetic nephropathy, established hypertensive
renal disease, and IgA nephropathy. As a group, these three
conditions represented the primary renal disease in 54% of
patients commencing renal replacement therapy in Australia
in 2006.10 Furthermore, multiple factors including the
absence of symptoms associated with renal dysfunction lead
to diagnosis of 25–50% of patients worldwide with CKD only
after they have established renal impairment.11 Therefore, for
many patients the therapeutic strategy of most benefit, aside
from control of hypertension, and possibly, use of statins12
and adherence to a low protein diet,13,14 is the use of
medications that ameliorate tubulointerstitial fibrosis.
Unfortunately, very few anti-fibrotic agents exist. Guide-
lines such as Kidney Disease and Quality Outcomes
Initiative15 and Caring for Australians with Renal Impair-
ment16 recommend use of angiotensin-converting enzyme
(ACE) inhibitors (ACEis) and angiotensin II receptor
blockers (ARBs) to delay the progression of CKD. However,
although such agents delay progression to ESRD they do not
prevent it altogether, and in fact how much of their benefit in
CKD is independent of their antihypertensive activity has
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been questioned.17 Limited efficacy has been attributed, at
least in part, to feedback effects on early components of the
renin–angiotensin–aldosterone system (RAAS), and the
angiotensin escape phenomenon.18
Aliskiren is the first commercially available, orally active,
renin inhibitor.19 There is much speculation that it will be
superior to ACEis and ARBs in preventing end-organ damage
in disease states, including renal disease.20 In this review the
rationale for superior nephroprotective activity of aliskiren
and the currently available evidence supporting this are
discussed.
ROLE OF THE RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM
IN PROGRESSIVE NEPHROPATHY
The enzymatic cascade involved in the RAAS is well known,
and is outlined in Figure 1. Renin, an aspartyl transferase,
cleaves angiotensinogen to yield angiotensin I (Ang I).21 Ang
I is converted to angiotensin II (Ang II) by ACE.22 ACE also
causes inactivation of bradykinins,23 which act as vasodila-
tors; this action of ACE may contribute to the therapeutic
actions of ACEis.24 Ang II has traditionally been considered
the main effector molecule of the RAAS,25 although there is
evidence to support a role of other angiotensin molecules
such as Ang(1–7) and Ang III and IV.26 Ang II exerts its
effects through the stimulation of the angiotensin II type I
receptor. Actions of Ang II include vasoconstriction,27
stimulation of the adrenal cortex to produce aldosterone,28
upregulation of transforming growth factor-b,29 and promo-
tion of inflammatory and proliferative events.26
Until recently, renin has been considered to play no role
other than in enzymatic activation of the RAAS. However,
there is now evidence to suggest that both renin and its
precursor, prorenin (earlier thought to be biologically inert),
have actions that are independent of the RAAS cascade. These
are thought to be mediated through the activation of the
(pro)renin receptor ((P)RR), first described by Nguyen
et al.21 In the kidney the (P)RR receptor is located in the
mesangial cells, smooth muscle cells of renal arteries, and
collecting ducts.30 Both renin and prorenin bind to the
(P)RR. Stimulation of the (P)RR in cultured mesangial cells
leads to rapid activation of the mitogen-activated protein
kinases p44( extracellular signal-regulated kinase (ERK)1)/
p42(ERK2),21 and increased production of plasminogen
activator 1 31 and transforming growth factor-b 32 indepen-
dently of enzymatic activity of renin. The binding of renin to
the (P)RR receptor also greatly enhances the enzymatic
activity of renin, thereby increasing activity of the RAAS
cascade.21
It is widely accepted that over-activity of the RAAS is
implicated in progressive renal disease.26 Increased actions of
both the systemic RAAS and the tissue (intra-renal) RAAS are
involved.33 The two broad ways in which the RAAS
perpetuates renal impairment are through hemodynamic
effects and remodeling. With regard to the former, Ang II
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Figure 1 | Schematic diagram showing the mechanisms of action of the renin–angiotensin system and sites of action of
antagonizing drugs (red squares). AT, angiotensin; BK, bradykinin; NO, nitric oxide; TGF-b, transforming growth factor-b.
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causes a greater degree of vasoconstriction in the efferent
than in the afferent glomerular arterioles,34 hence intraglo-
merular hypertension. Systemic hypertension is also seen in
hyper-reninemic states.22 Ang II causes vasoconstriction at
the level of the glomerular capillaries, hence modulates
glomerular filtration.35 Remodeling effects include increased
production of connective tissue and deposition of extra-
cellular matrix, stimulation of apoptosis, and chemoattrac-
tant activity leading to infiltration of macrophages and other
inflammatory cells.36
CURRENTLY AVAILABLE ANTAGONISTS OF THE RAAS
The two families of RAAS antagonists used most commonly
in clinical practice are the ACEis and ARBs. Many of the large
studies in this area have targeted patients with diabetes
mellitus (both type I and II); however, RAAS blockade is
advocated in many forms of renal disease, particularly when
proteinuria is present.
Large multicenter trials have shown the benefits of
angiotensin blockade in diabetes mellitus. Lewis et al. showed
in 1983 that captopril attenuated the progression of renal disease
in a cohort of patients with type I diabetes mellitus.37 More
recently the ARBs, irbesartan38,39 and losartan,40 were found to
delay progression of nephropathy in patients with type II
diabetes. Importantly, in the Irbesartan in Diabetic Nephropathy
Trial,38 patients with established renal disease derived benefit
from irbesartan in addition to those with only microalbuminur-
ia. A vast number of other trials of ACEis and ARBs in renal
disease have been performed under a number of conditions.
The effects of ACEis and ARBs in clinical trials include
reduction of albuminuria and proteinuria, slowing of the
decline in glomerular filtration rate, and decrease in the
number of patients to reach the endpoints of doubling of the
serum creatinine or the development of ESRD. The
renoprotective effects of ACEis and ARBs are in excess of
effects expected from their blood pressure-lowering actions
alone, inferring that the blockade of the RAAS is an
important part of their mechanism of action.
Despite the benefits of angiotensin blockade, patients
receiving this treatment still develop ESRD. The incomplete
response has been attributed in part to feedback effects
arising from the blockade of the RAAS. Within 6 months of
commencing treatment with ACEis, Ang II levels return to
baseline, the so-called ‘angiotensin escape phenomenon’.18
Increased plasma renin levels and plasma renin activity
(PRA) have been documented after treatment with ACEis
and ARBs. Consequent increased activity of renin, including
that at the (P)RR receptor, may aid in the progression of
nephropathy.
A further limiting factor of angiotensin blockade in some
patients is aldosterone escape.41 Spironolactone is an
aldosterone antagonist that competes with aldosterone for
the intracellular aldosterone receptor. A recently published
open-label, randomized, cross-over study of 20 patients with
non-diabetic proteinuric CKD found that the mean urinary
protein excretion in patients who received triple therapy
(spironolactone, an ACEi, and an ARB) was 0.7 g every 24 h
less than in patients receiving dual therapy (an ACEi and
an ARB).42 Triple therapy also reduced urinary excretion of
N-acetyl-b-D-glucosaminidase and amino-terminal peptide
of collagen III.
ALISKIREN
Aliskiren is an orally active non-peptidic renin inhibitor that
is highly specific for renin.43 The chemical structure of
aliskiren is shown in Figure 2. It acts by binding to the active
site of renin, thereby inhibiting catalytic activity.44 As renin
acts at the rate-limiting step in the RAAS cascade, the
blockade of renin with aliskiren may cause more complete
inhibition of the RAAS, and reduce the feedback effects when
compared with ACEis and ARBs. In addition, the blockade of
renin may reduce activity at the (P)RR. Therefore, aliskiren
may provide superior reno-protection.
At present there is only one published clinical trial of
aliskiren in nephropathy.45 Therefore, the majority of
information about renoprotective benefits must be inferred
from studies of the effects of aliskiren on the RAAS, cell
culture studies considering the mechanisms of action of
aliskiren, and experimental models of nephropathy.
Effects of aliskiren on the RAAS
Clinical studies that have evaluated the effects of aliskiren on
the RAAS are summarized in Table 1. Azizi et al. showed that
in healthy human volunteers maintained on a high sodium
diet a single 300 mg dose of aliskiren caused a reduction in
PRA and Ang I and II levels within 1 h of administration. In
contrast, the ARB, valsartan, increased each of these
parameters. Immunoreactive renin release was increased by
both aliskiren and valsartan.46 Combination therapy with
valsartan and aliskiren neutralized the increases in PRA, Ang
I, and Ang II seen with valsartan alone. The reduction in
mean arterial pressure was similar among all groups,
indicating that the results were independent of antihyperten-
sive effects. Similar results were obtained by the same authors
in a study of healthy volunteers who were mildly sodium
depleted.47
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Figure 2 | Chemical structure of aliskiren.
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Table 1 | Summary of clinical trials in which the effects of aliskiren on components of the renin–angiotensin system have been
evaluated
Intervention
Study
Subjects/
inclusion criteria n 1 2 3 Results
aStudies in healthy subjects
Nussberger
et al. 200248
Healthy male
volunteers
100 mmol/d
sodium diet
18 Aliskiren 40 mg p.o.
o.d. for 8 days
AND
aliskiren 80 mg p.o.
o.d. for 8 days
Aliskiren 160 mg
p.o. o.d. for 8 days
AND
aliskiren 640 mg
p.o. o.d. for 8 days
Enalapril 20 mg
p.o. o.d.
Plasma renin activity
k with aliskiren
m with enalapril
Plasma renin concentration
mm with aliskiren (dose
20 fold m with 640 mg)
10 fold m with enalapril
Angiotensin II
76% k with aliskiren 640 mg days
1 and 8
57% k with enalapril
Angiotensin I
k with aliskiren
m with enalapril
plasma aldosterone
k compared with placebo in all
groups except 40 mg aliskiren;
duration 24 h for aliskiren vs 6 h
for valsartan
no change by day 8
Urinary aldosterone excretion
56% k day 1 and 31% k day 8
with aliskiren
k with enalapril (P=NS)
aAzizi et al.
200447
Normotensive
Caucasian males
Mildly sodium
depleted
12 Aliskiren 300 mg p.o.
(single dose)
Valsartan 160 mg
p.o. (single dose)
Aliskiren 150 mg
p.o. + valsartan
80 mg p.o. (single
doses)
Plasma renin activity
kk with aliskiren
m with valsartan
k with combination therapy
Plasma renin concentration
mm all groups
Plasma angiotensin I and II
kk with aliskiren
mm with valsartan
2 combination therapy
Plasma aldosterone
k in all groups for 6 h
Urinary aldosterone excretion
k in all groups; duration 24 h for
aliskiren and combination therapy
vs 8–12 h for valsartan
aAzizi et al.
200746
Normotensive
Caucasian males
Sodium replete
12 Aliskiren 300 mg p.o.
(single dose)
Valsartan 320 mg
p.o. (single dose)
Aliskiren
150 mgþ
valsartan 160 mg
po (single doses)
Plasma renin activity
kk with aliskiren
m with valsartan
2 with combination therapy
Plasma renin concentration
mm with aliskiren and valsartan
m with combination therapy
Plasma angiotensin I and II
Paralleled changes in plasma
renin activity
Plasma aldosterone
k in all groups for 4–8 h
Urinary aldosterone
k in all groups; duration 48 h for
aliskiren and combination therapy
vs 18 h for valsartan
Table 1 continued on following page
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Nussberger et al.48 compared the effects of aliskiren and
the ACEi, enalapril, in 18 healthy male volunteers maintained
on a 100 mmol/day sodium diet for 8 days. Daily aliskiren
doses of 80, 160, and 640 mg (but not 40 mg) reduced plasma
Ang II levels in a dose-dependent manner. There was a
similar reduction in Ang II with 20 mg of enalapril, although
Table 1 | Continued
Intervention
Study
Subjects/
inclusion criteria n 1 2 3 Results
aStudies in disease states
Nussberger
et al. 200749
Mean sitting
diastolic BP
95–110 mm Hg
569 Aliskiren 150 mg,
300 mg or 600 mg
p.o. o.d.
Irbesartan 150 mg
p.o. o.d.
Plasma renin activity
69, 71, and 75% k with aliskiren;
150, 300, and 600 mg
109% m with irbesartan
Plasma renin concentration
157, 246, and 497% m with
aliskiren 150, 300, and 600 mg;
105% m with irbesartan
O’Brien et al.
200750
Daytime systolic
ABPMX140 &
p180 mm Hg
67 Aliskiren 150 mg p.o.
o.d. (+ HCTZ if ABPM
Z135/85 mmHg)
Aliskiren 75 mg
p.o. o.d. for 3
weeks then
150 mg p.o.
o.d.þ ramipril
5 mg p.o. o.d.
Aliskiren 75 mg
p.o. o.d. for 3
weeks then
150 mg p.o.
o.d.þ irbesartan
150 mg p.o. o.d.
Plasma renin activity
65% k with aliskiren
90% m with ramipril
175% m with irbesartan
2 any combination therapy
aVillamil et al.
200751
Mean sitting
diastolic BP
95–110 mm Hg
2776 Aliskiren 75 mg,
150 mg or 300 mg
p.o. o.d.
HCTZ 6.25 mg,
12.5 mg or 25 mg
p.o. o.d.
Combination
therapy (factorial
design; alsikiren/
HCTZ 300/
6.25 mg excluded)
Plasma renin activity
54.2, 65.1, and 57.6% k with
aliskiren 75, 150, and 300 mg;
3.5, 44.7, and 71.9%m with
HCTZ 6.25, 12.5, and 25 mg;
46.1–63.5% k with combination
therapy
Plasma renin concentration
164, 192, and 348% m with
aliskiren 150, 300, and 600 mg;
108% m with HCTZ 25 mg;
2 with HCTZ 6.25 and 12.5 mg;
m with combination therapy
(dose-related effect)
aSeed et al.
200753
NYHA class II-IV
CHF
EFo35%
450 years old
27 Aliskiren 300 mg p.o.
o.d. (dose titrated
upward from 75 mg)
Ramipril 10 mg
p.o. o.d. (dose
titrated upward
from 5 mg)
Placebo
(4 patients,
one week only)
Plasma renin activity
k with aliskiren, m with ramipril
Plasma angiotensin II
k with aliskiren, 2 with ramipril
Plasma aldosterone
No change with any treatment
Uresin et al.
200752
Type I or II
diabetes mellitus
Stage 1–2
hypertension
837 Aliskiren 150 mg p.o.
o.d. for 4 weeks, then
300 mg p.o. o.d.
Ramipril 5 mg p.o.
o.d. for 4 weeks,
then 10 mg p.o.
o.d.
Aliskiren 50 mg
p.o. o.d.þ ramipril
5 mg p.o. o.d. for
4 weeks, then
aliskiren 100 mg
p.o. o.d.þ ramipril
10 mg p.o. o.d.
Plasma renin activity
66% k with aliskiren
106% m with ramipril
48% k with combination therapy
Plasma renin concentration
139% m with aliskiren
72% m with ramipril
331% m with combination
therapy (Po0.001 vs
monotherapy)
Plasma aldosterone
No change with monotherapy
(8% k with aliskiren,
2% k with ramipril)
18% k with combination therapy
(P¼ 0.034 vs baseline)
ABPM, ambulatory blood pressure monitoring; BP, blood pressure; EF, ejection fraction; HCTZ, hydrochlorothiazide; NYHA class II–IV CHF, New York Heart Association class
II–IV congestive heart failure.
aPlacebo controlled.
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maximal Ang II suppression occurred after 1 h with aliskiren
and after 6 h with enalapril. Ang I and PRA were reduced by
aliskiren in parallel to Ang II, in contrast to enalapril, which
increased PRA and Ang I by more than 15-fold on day 1. The
effects of both drugs on Ang I and II and PRA were similar on
days 1 and 8. Active renin levels were markedly increased
with 640 mg of aliskiren to 20-fold more than with placebo.
This was greater than enalapril, which increased plasma renin
10-fold compared with placebo.
In addition to studies of normotensive individuals a
number of investigators have considered the effects of
aliskiren in hypertensive patients,49–51 people with diabetes
and hypertension,52 and patients with New York Heart
Association Class II–IV heart failure.53 These studies are
particularly relevant to the use of aliskiren as treatment for
CKD as hypertension and diabetes mellitus are risk factors
for the development of CKD, and the prevalence of CKD in
patients with heart failure is greater than in the general
population. A consistent finding in these studies was a
decrease in PRA with aliskiren in contrast to an increase seen
with comparator drugs including ACE inhibitors, ARBs, and
thiazide diuretics.
Six of the studies listed in Table 1 considered the effects of
aliskiren on plasma aldosterone and/or urinary aldosterone
excretion. Plasma aldosterone was variably reported to be
either unchanged or reduced for up to 24 h. It should be
noted that Nussberger found that in healthy volunteers
plasma aldosterone was reduced on day 1 but not after day
8.48 In the same study urinary aldosterone excretion was
reduced on day 1, with persistent, albeit attenuated,
suppression at day 24.
The increase in active or immunoreactive renin reported
in the above studies has led to the suggestion that this
may negate the beneficial effects of aliskiren.54 However,
Menard et al.55 report that renin inhibitors interact with
monoclonal antibodies used in commercially available renin
assays, and that factors such as incubation time may affect
the results of such assays. In rat aortic vascular smooth
muscle cells aliskiren causes conformational change in
prorenin from ‘closed’ to ‘open’ and thus allows detection
of prorenin in active renin assays.56 These factors suggest that
the implications of rises in active renin require further
clarification.
Fisher et al.57 studied changes in renal plasma flow, as a
marker of intra-renal RAAS activity, in healthy volunteers
who were administered aliskiren. They found that aliskiren
increased renal plasma flow in a dose-dependent manner,
with persisting effects 48 h after a single dose of aliskiren. The
peak rise in renal plasma flow, achieved with a 600 mg dose of
aliskiren, was greater than that seen with 25 mg of captopril, a
dose that had been shown earlier to exceed the top of the
vascular response curve.58
Cell culture studies
Aliskiren has been shown to reduce activity of the RAAS in
cell culture studies. In cultured podocytes exposed to glucose,
pre-incubation with aliskiren decreased the upregulation of
angiotensin II. Upregulation of Ang II in this study was
believed to be a consequence of increased renin activity, as
evidenced by an increased expression of renin following
glucose exposure.59
There is a growing body of evidence from cell
culture studies to suggest that aliskiren does not antagonize
the (P)RR. Feldman et al.60 showed that binding of
aliskiren to prorenin occurs in a dose-dependent manner.
However, aliskiren did not reduce the binding of renin
to the (P)RR receptor in mesangial cells, or prevent ERK
activation (a downstream mediator of renin receptor
activation). Gene expression of the (P)RR in mesangial
cells, measured by real-time reverse transcription polymerase
chain reaction, was not altered by treatment with
aliskiren. In human embryonic kidney cells (HEK293)
aliskiren did not alter the effects of prorenin and renin on
the (P)RR.61 (P)RR activity was evaluated by measuring
mRNA and protein levels of the (P)RR and PI3K-p85a, a
downstream target gene of the (P)RR, both markers of
apoptosis.
Similar findings have been reported in studies of non-kidney
cell lines. In neonatal rat cardiomyocytes, aliskiren failed to
prevent prorenin-induced upregulation of genes downstream of
p38 mitogen-activated protein kinase, which are involved in the
regulation of actin filaments.62 Similarly, Feldt et al.63 found that
aliskiren did not inhibit the binding of (pro)renin to the (P)RR,
or prevent (pro)renin-induced ERK 1/2 phosphorylation and
kinase activity in human and U937 monocytes. The same group
reported similar findings for cultured vascular smooth muscle
cells,64 as did Batenburg et al.56
Experimental models of nephropathy
Feldt et al.64 studied aliskiren in double transgenic rats that
overexpress both human renin and angiotensinogen genes.
Aliskiren reduced blood pressure and normalized the levels of
cystatin C, albuminuria and neutrophil gelatinase-associated
lipocalin (a marker of tubular damage) at 7 weeks. All
aliskiren-treated rats were alive at study completion. In
contrast, the mortality rate was 58% in rats treated with the
handle region decoy peptide, which blocks the renin/prorenin
receptor, and the handle region decoy peptide had no effect
on the parameters of renal damage.
In streptozotocin-induced diabetes mellitus in transgenic
Ren(2) rats, a model of advanced diabetic nephropathy in
humans,65 aliskiren reduced albuminuria and glomerulo-
sclerosis to a similar extent as the ACE inhibitor, perindo-
pril.66 This effect was seen despite the fact that aliskiren did
not lower blood pressure as much as perindopril. Reduction
in tubulointerstitial fibrosis was significantly greater in
aliskiren-treated diabetic rats compared with the perindo-
pril-treated animals. In this study, albuminuria was sig-
nificantly correlated with blood pressure in control, untreated
diabetic, and perindopril-treated diabetic rats. However,
there was no correlation between albuminuria and blood
pressure in the aliskiren group, suggesting that measures
28 Kidney International (2009) 76, 23–31
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other than reduction in systemic blood pressure were
important in reducing albuminuria.
Feldman et al.60 also studied diabetic nephropathy in
transgenic Ren(2) rats. In this study diabetes was induced at
8.5–9.5 weeks of age, and treatment with either aliskiren or
vehicle was commenced within 24 h of streptozotocin
injection, and was continued for 10 weeks. As expected,
aliskiren reduced mean arterial pressure. Rats treated with
aliskiren did not develop albuminuria, in contrast to control
rats, which had a progressive rise in 24-h urinary albumin
excretion over the study period. Aliskiren therapy was
associated with reduced cortical gene expression of trans-
forming growth factor-b1 and collagen I, but not collagens III
and IV. Renin gene expression was increased by aliskiren
treatment. Expression of the (P)RR, evaluated by in situ
hybridization, was seen to occur in glomeruli and tubules
and, to a lesser extent, in the renal arteries in vehicle-treated
diabetic rats. Aliskiren attenuated the expression of the
(P)RR.
Human study in nephropathy
Results of the first published clinical trial to consider the
renoprotective effects of aliskiren were recently reported by
Parving et al.45 in the New England Journal of Medicine.
This multicenter, international trial studied 599 patients who
had type 2 diabetes mellitus, hypertension, and diabetic
nephropathy, defined as an early morning albumin-
to-creatinine ratio of 4300 mg/g, or 4200 mg/g in patients
taking medications that antagonized the RAAS. Combination
therapy with maximal doses of losartan (100 mg daily)
and aliskiren (150 mg daily for 3 months, then 300 mg
daily for a further 3 months) was compared with losartan
and placebo. Treatment with aliskiren and losartan
was superior to losartan and placebo, as evidenced by a
20% reduction in albuminuria compared with placebo
(Po0.001). This effect seemed to be independent of
blood pressure.
CONCLUSIONS AND FUTURE RESEARCH DIRECTION
Aliskiren is the first commercially available orally active
renin inhibitor. In both healthy volunteers and those with
disease states, aliskiren reduces angiotensin II levels and
PRA without stimulating compensatory increases in PRA,
Ang I and Ang II as seen with ACE inhibitors and ARBs.
However, aliskiren does cause a rise in active renin levels,
the significance of which is unclear. Further, suppression
of urinary aldosterone excretion and plasma aldosterone
levels by aliskiren is incomplete and short-lived. In vitro
studies suggest that aliskiren does not antagonize the (P)RR;
therefore it is unlikely to change the non-enzymatic actions
of renin.
To date, studies of experimental nephropathy, and one
large well-designed study in humans, have shown promising
results for aliskiren as a treatment for nephropathy. However,
although the results reported by Parving et al. regarding the
use of aliskiren in diabetic nephropathy are encouraging, they
are far from conclusive. Although albuminuria is an accepted
surrogate endpoint in trials of nephropathy, studies
considering end points such as progression to ESRD
and/or doubling of serum creatinine are required. The
question of whether aliskiren is superior or equivalent to
losartan was not addressed. As the authors acknowledge in
their discussion, a further unanswered question is whether
the combination of aliskiren and losartan is superior to
ACEi/ARB combinations.
Further studies of aliskiren as a renoprotective agent are
required, with a particular emphasis on comparison with
ACEis and ARBs. Use of aliskiren in combination with other
agents that antagonize the RAAS should also be explored. In
particular, as there is incomplete suppression of aldosterone
by aliskiren, studies of combination therapy with aliskiren
and spironolactone may be of interest. Unfortunately, fiscal
concerns may provide a practical barrier to such research; at
present aliskiren is more expensive than other antihyperten-
sives, which may be a prohibitive factor in future drug trials.
Another consideration will be the recently published results
of renal outcomes in the ongoing Telmisartan Alone and in
Combination with Ramipril Global Endpoint Trial,67 In the
Ongoing Telmisartan Alone and in Combination with
Ramipril Global Endpoint Trial, the rate of progression to
ESRD or doubling of the serum creatinine was greater in
patients treated with dual therapy (telmisartan and ramipril)
than monotherapy. This result raises questions about the
safety of dual RAAS blockade.
In conclusion, aliskiren is an effective antihypertensive
agent that theoretically offers superior renoprotection to
currently available agents. Further studies are required to
evaluate this hypothesis in more detail. Such studies should
be carefully designed to ensure they have clinically relevant
endpoints.
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